Developments in pertussis immunisation in Japan

Kimura, Mikio; Kuno-Sakai, Harumi

doi:10.1016/0140-6736(90)91530-n

Cited by 82 publications

(18 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Widespread acceptance of vaccines can only be assured if the public believes vaccines will not harm them. Concerns about vaccine safety led to marked drops in pertussis vaccine coverage in Japan and the United Kingdom in the 1970s, with resultant major epidemics of whooping cough (2,3). The quest for life-long protection needs to be accompanied by a quest for completely safe products.…”

mentioning

confidence: 99%

Quest for life-long protection by vaccination.

Dowdle¹,

Orenstein²

1994

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Quest for life-long protection by vaccination.

Dowdle¹,

Orenstein²

1994

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…There is considerable evidence to support the inclusion of pertussis toxoid (PT) and filamentous haemagglutinin (FHA) in acellular pertussis vaccines [1,10,15,16,20]. Pertussis toxin is the major toxin involved in the pathology of pertussis, and FHA plays a role in bacterial adhesion.…”

Section: Introductionmentioning

confidence: 99%

Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous haemagglutinin and 69 kDa outer membrane protein as a booster in children

Kanra

Ceyhan

Vandevoorde³

et al. 1993

Eur J Pediatr

View full text Add to dashboard Cite

In two double-blind, randomized, comparative studies involving a total of 218 children, an acellular pertussis (DTPa) vaccine containing diphtheria and tetanus toxoids and pertussis components filamentous haemagglutinin (FHA), pertussis toxoid (PT), and 69 kDa outer membrane protein (69 kDa OMP) was administered as a booster to 17-month-old and 5-year-old children with a history of routine whole-cell diphtheria-tetanus-pertussis (DTPw) vaccination. The control groups in these studies received DTPw vaccine. Among 17-month-old toddlers, significantly lower proportions of DTPa vaccine recipients had local pain (7.3%), redness (14.5%) and swelling (9.1%) than DTPw vaccine recipients (23.6%, 30.9% and 23.6%, respectively). A trend toward fewer local reactions was also seen in 5-year-old children vaccinated with DTPa in private practice and public clinics although differences were not statistically significant. Fever (rectal temperature > or = 38 degrees C) was reported more frequently for DTPw vaccine recipients in both age groups. While no differences existed between groups in terms of geometric mean antibody titres (GMTs) prior to booster vaccination, anti-PT antibody GMTs were higher among DTPa vaccine recipients than among DTPw vaccine recipients after booster vaccination. The difference was statistically significant in 5-year-old subjects. Furthermore, significantly higher anti-FHA and anti-69 kDa OMP GMTs were seen in DTPa vaccine recipients in both age groups. In pre-vaccination seropositive subjects and in pre-vaccination seronegative subjects the rate of immune response to pertussis antigens was higher for DTPa than for DTPw vaccine recipients with the exception of the rate of response induced to 69 kDa OMP in 5-year-old children.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

“…53 Focusing on hospitalizations, which are less sensitive to surveillance artifacts, various studies have found incidences ranging from 50-90 per 100,000 infants <1 year. 11,13,62 Further, circulation among adolescents and adults has remained high after the switch from Pw to Pa vaccines.…”

Section: Measures Implemented To Improve Protection Against Pertussismentioning

confidence: 99%

“…53 Nowadays, almost all European countries, Canada, the US and Japan have introduced a preschool booster vaccination with Pa vaccine for children ages 4-7 yrs in their national immunization schedule. 53,60,62,63 In most countries, the preschool booster consists of a combination of Pa vaccine with DT(IPV) and the coverage is generally high. The effectiveness of the preschool booster has been demonstrated in the Netherlands.…”

Section: Measures Implemented To Improve Protection Against Pertussismentioning

confidence: 99%